Juan Pablo Idrovo1, Weng-Lang Yang2, Asha Jacob2, Lana Corbo1, Jeffrey Nicastro1, Gene F Coppa1, Ping Wang3. 1. Department of Surgery, Hofstra North Shore-LIJ School of Medicine, Manhasset, New York. 2. Department of Surgery, Hofstra North Shore-LIJ School of Medicine, Manhasset, New York; Center for Translational Research, The Feinstein Institute for Medical Research, Manhasset, New York. 3. Department of Surgery, Hofstra North Shore-LIJ School of Medicine, Manhasset, New York; Center for Translational Research, The Feinstein Institute for Medical Research, Manhasset, New York. Electronic address: pwang@nshs.edu.
Abstract
BACKGROUND: Sepsis is a life-threatening acute inflammatory condition associated with metabolic complications. Accumulation of free fatty acids (FFAs) induces inflammation and causes lipotoxic effects in the liver. Because fatty acid metabolism plays a role in the inflammatory response, we hypothesized that the administration of C75, a fatty acid synthase inhibitor, could alleviate the injury caused by sepsis. METHODS: Male mice were subjected to sepsis by cecal ligation and puncture (CLP). At 4 h after CLP, different doses of C75 (1- or 5-mg/kg body weight) or vehicle (20% dimethyl sulfoxide in saline) were injected intraperitoneally. Blood and liver tissues were collected at 24 h after CLP. RESULTS: C75 treatment with 1- and 5-mg/kg body weight significantly lowered FFA levels in the liver after CLP by 28% and 53%, respectively. Administration of C75 dose dependently reduced serum indexes of organ injury (aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase) and serum levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). In the liver, C75 treatment reduced inflammation (TNF-α and IL-6) and oxidative stress (inducible nitric oxide synthase and cyclooxygenase 2) in a dose-dependent manner. The 5-mg dose improved the 10-d survival rate to 85% from that of 55% in the vehicle. In the presence of C75, TNF-α release in RAW 246.7 cells with 4-h lipopolysaccharide stimulation was also significantly reduced. CONCLUSIONS: C75 effectively lowered FFA accumulation in the liver, which was associated with inhibition of inflammation and organ injury as well as improvement in survival rate after CLP. Thus, inhibition of FFA by C75 could ameliorate the hepatic dysfunction seen in sepsis.
BACKGROUND:Sepsis is a life-threatening acute inflammatory condition associated with metabolic complications. Accumulation of free fatty acids (FFAs) induces inflammation and causes lipotoxic effects in the liver. Because fatty acid metabolism plays a role in the inflammatory response, we hypothesized that the administration of C75, a fatty acid synthase inhibitor, could alleviate the injury caused by sepsis. METHODS: Male mice were subjected to sepsis by cecal ligation and puncture (CLP). At 4 h after CLP, different doses of C75 (1- or 5-mg/kg body weight) or vehicle (20% dimethyl sulfoxide in saline) were injected intraperitoneally. Blood and liver tissues were collected at 24 h after CLP. RESULTS: C75 treatment with 1- and 5-mg/kg body weight significantly lowered FFA levels in the liver after CLP by 28% and 53%, respectively. Administration of C75 dose dependently reduced serum indexes of organ injury (aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase) and serum levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). In the liver, C75 treatment reduced inflammation (TNF-α and IL-6) and oxidative stress (inducible nitric oxide synthase and cyclooxygenase 2) in a dose-dependent manner. The 5-mg dose improved the 10-d survival rate to 85% from that of 55% in the vehicle. In the presence of C75, TNF-α release in RAW 246.7 cells with 4-h lipopolysaccharide stimulation was also significantly reduced. CONCLUSIONS: C75 effectively lowered FFA accumulation in the liver, which was associated with inhibition of inflammation and organ injury as well as improvement in survival rate after CLP. Thus, inhibition of FFA by C75 could ameliorate the hepatic dysfunction seen in sepsis.
Authors: Sylas B Cappi; Danilo T Noritomi; Irineu T Velasco; Rui Curi; Tatiana C A Loureiro; Francisco G Soriano Journal: Intensive Care Med Date: 2012-02-02 Impact factor: 17.440
Authors: Nina E Murugina; Anna S Budikhina; Yulia A Dagil; Polina V Maximchik; Lyudmila S Balyasova; Vladimir V Murugin; Mikhail V Melnikov; Viktoriya S Sharova; Anna M Nikolaeva; Georgy Z Chkadua; Boris V Pinegin; Mikhail V Pashenkov Journal: J Biol Chem Date: 2020-01-31 Impact factor: 5.157
Authors: Adam Khader; Weng-Lang Yang; Laura W Hansen; Salil R Rajayer; Jose M Prince; Jeffrey M Nicastro; Gene F Coppa; Ping Wang Journal: J Surg Res Date: 2017-07-10 Impact factor: 2.192
Authors: Srikanth Elesela; Susan B Morris; Samanthi Narayanan; Surinder Kumar; David B Lombard; Nicholas W Lukacs Journal: PLoS Pathog Date: 2020-02-27 Impact factor: 6.823
Authors: Brett Montague; April Summers; Ruchika Bhawal; Elizabeth T Anderson; Sydney Kraus-Malett; Sheng Zhang; Robert Goggs Journal: PLoS One Date: 2022-07-08 Impact factor: 3.752
Authors: Cassiano Felippe Gonçalves-de-Albuquerque; Ina Rohwedder; Adriana Ribeiro Silva; Alessandra Silveira Ferreira; Angela R M Kurz; Céline Cougoule; Sarah Klapproth; Tanja Eggersmann; Johnatas D Silva; Gisele Pena de Oliveira; Vera Luiza Capelozzi; Gabriel Gutfilen Schlesinger; Edlaine Rijo Costa; Rita de Cassia Elias Estrela Marins; Attila Mócsai; Isabelle Maridonneau-Parini; Barbara Walzog; Patricia Rieken Macedo Rocco; Markus Sperandio; Hugo Caire de Castro-Faria-Neto Journal: Front Immunol Date: 2018-04-30 Impact factor: 7.561